Zealand Pharma Sells Rusfertide Royalty to Royalty Pharma for $100 Million
Zealand Pharma sold its legacy economic interests in rusfertide, Takeda’s investigational hepcidin-mimetic therapy for polycythemia vera, to Royalty Pharma for $100 million—$50 million upfront and $50 million on the first anniversary of closing. Zealand…
